perspectives
We are passionate about using our voices to advance our mission of developing life-transforming therapies for people living with serious muscle diseases.
We are passionate about using our voices to advance our mission of developing life-transforming therapies for people living with serious muscle diseases.
Sep 15, 2021
Starting a New Tradition of Support
by Molly White, Dyne’s vice president, global head of patient advocacy and engagement
Read more
Jul 8, 2021 |

Playing To Win: Building A Position Of Strength In Biotech

by Josh Brumm

Read more
April 28, 2021 | BLOG

Toward a brighter future: targeting the genetic basis of rare muscle diseases

By Romesh Subramanian, Ph.D.

Read more
April 8, 2021 | BLOG

Scaling culture with growth: how to maintain your startup’s “special sauce”

By Joshua Brumm

Read more
Jan 8, 2021 | Life Science Leader panel

Preparing to pitch in a virtual world

Featuring Joshua Brumm

Watch
Dec 16, 2020 | BLOG

Beyond the balance sheet: thinking broadly about dilution in building a transformative biotech

By Joshua Brumm

Read more
Dec 14, 2020 | BLOG

Voice of the patient – the biopharma perspective

By Molly White

Read more
Oct 21, 2020 | PODCAST

FSHD Society Radio

By Molly White

Listen
Oct 13, 2020 | BLOG

The power of hope: a joint perspective on finding balance in the search for life-changing therapies

By Joachim Boekelmann and Joshua Brumm

Read more
April 30, 2020 | BLOG

Ordinary people achieving the extraordinary: lessons in leadership from the court to the c-suite

By Joshua Brumm

Read more
additional content
What does #themuscletokeeplife moving mean to us at Dyne?
watch
How does Dyne go above and beyond for patients?
watch
Stay connected with us on
Twitter, LinkedIn, and Facebook

Hear more from Dyne Therapeutics

Starting on Monday, we’ll be at the @OTSociety Virtual Conference – visit our virtual booth to learn more about our programs! Register here: https://bit.ly/2XBNZIA

Hear more from our CEO, Joshua Brumm

I’m thrilled to join Amphista as Chairman and I’m looking forward to the opportunity we have to advance a unique approach to targeted protein degradation and develop transformational therapies for patients. https://prn.to/3AvD95l